Cerep SA offers in vitro pharmacology, in vitro ADME-Tox and in vivo PK services, and provides solutions allowing faster and cost-effective drug discovery by identifying at early stages the most promising drug candidates as well as eliminating those compounds likely to fail in development. Cerep’s services benefit annually to about 500 pharmaceutical and biotechnological companies worldwide including most of the top pharmaceutical firms.